» Articles » PMID: 10455367

Comparison of the Classic Glucksberg Criteria and the IBMTR Severity Index for Grading Acute Graft-versus-host Disease Following HLA-identical Sibling Stem Cell Transplantation. International Bone Marrow Transplant Registry

Overview
Specialty General Surgery
Date 1999 Aug 24
PMID 10455367
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Acute graft-versus-host disease (AGVHD) severity is usually graded (grades 0-IV) by the pattern of organ involvement using the classic Glucksberg-Seattle criteria (GSC). Recently, the International Bone Marrow Transplant Registry (IBMTR) developed a new Severity Index by regrouping the patterns of organ involvement into five Indexes (0-D) that appeared more predictive of transplant-related mortality (TRM) and transplant failure (TF, relapse or TRM). We studied the predictive value of both grading systems of TRM, TF and GVHD-related mortality (GTRM) in a series of 114 consecutive patients > or = 12 years old allografted from a histocompatible sibling at our institution, 100 of whom were evaluable for AGVHD. The IBMTR Severity Index showed better incremental prediction of TRM (relative risks (RR) of 1, 1.5, 1.4, 2 and 2.5 for Indexes 0, A, B, C and D), TF (RRs of 1, 1.6, 1.6, 2 and 2.3, respectively) and GTRM (RRs of 1, 2.2 and 4.8 for Indexes B, C and D) than the GSC. With the GSC different outcomes for TRM and TF were found only from grade 0 to I-II and 0 to IV or I-III to IV, but not from I-II to III. The GSC also appeared less predictive of GTRM (RRs of 1, 0.4 and 2.9 for grades II, III and IV). In our relatively small patient sample, the new IBMTR Severity Index appeared more predictive of transplant outcome than the GSC, especially between no AGVHD, early Indexes (A-B) and advanced Indexes (C-D).

Citing Articles

Haploidentical hematopoietic stem cell transplantation as a first-line treatment for paediatric severe aplastic anemia: a single-center research.

Yuan M, Jia C, Ma J, Zhang M, Zhu G, Wang B Int J Med Sci. 2024; 21(6):1027-1036.

PMID: 38774762 PMC: 11103391. DOI: 10.7150/ijms.94012.


Matched unrelated donor transplantation versus haploidentical transplantation with post-transplant cyclophosphamide in children with acute myeloid leukemia: a PDWP-EBMT study.

Ruggeri A, Santoro N, Galimard J, Kalwak K, Algeri M, Zubarovskaya L Haematologica. 2024; 109(7):2122-2130.

PMID: 38186346 PMC: 11215360. DOI: 10.3324/haematol.2023.284445.


Acute GVHD classification based on the dynamics of GVHD skin involvement from its appearance to the start of systemic treatment.

Milone G, Leotta S, Giuffrida G, Milone G, Sapuppo G, Giunta G Bone Marrow Transplant. 2023; 59(1):17-22.

PMID: 37749188 DOI: 10.1038/s41409-023-02107-z.


miR-155 and miR-92 levels in ALL, post-transplant aGVHD, and CMV: possible new treatment options.

Iravani Saadi M, Nikandish M, Ghahramani Z, Valandani F, Ahmadyan M, Hosseini F J Egypt Natl Canc Inst. 2023; 35(1):18.

PMID: 37332027 DOI: 10.1186/s43046-023-00174-3.


Acute Graft-versus-Host Disease: An Update on New Treatment Options.

Patel D, Crain M, Pusic I, Schroeder M Drugs. 2023; 83(10):893-907.

PMID: 37247105 DOI: 10.1007/s40265-023-01889-2.